Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2024-01-08 08:01:09 ET Summary Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the 3rd quarter of 2023, which left mixed feelings. ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
2023-11-15 13:13:57 ET More on Merck, Pfizer, etc. Pfizer: Victim Of Vaccine Side Effects High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript) Pfizer to shed 500 ...
2023-11-12 22:45:00 ET Summary Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic...
2023-10-31 09:33:16 ET More on Daiichi Sankyo Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations Merck to pay up to $22B in cancer drug deal with Daiichi Sankyo As...
2023-10-30 07:39:24 ET More on Deciphera Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Deciphe...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...